China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical ...
China Pharma Holdings, Inc. (CPHI) is a China-based specialty pharmaceutical manufacturer focused on the development, production, and marketing of pharmaceutical and related biochemical products. The company’s business model centers on supplying a broad portfolio of prescription and OTC-style medicines across multiple therapeutic areas, with distribution primarily into mainland China. From ...China Pharma Holdings, Inc. (CPHI) is a China-based specialty pharmaceutical manufacturer focused on the development, production, and marketing of pharmaceutical and related biochemical products. The company’s business model centers on supplying a broad portfolio of prescription and OTC-style medicines across multiple therapeutic areas, with distribution primarily into mainland China.
From a product perspective, CPHI’s portfolio includes formulations such as powdered and liquid injectables, oral tablets, capsules, and other dosage forms, including cephalosporin-based oral solutions. Therapeutic areas highlighted in its description include (i) neurological and cognitive health (e.g., Cerebroprotein Hydrolysate and Gastrodin injectables), (ii) cardiovascular and cerebrovascular conditions (e.g., Propylgallate and Ozagrel Sodium, as well as Alginic Sodium Diester), (iii) anti-infectives (for example Roxithromycin dispersible tablets; Cefaclor, Cefalexin, Clarithromycin, and Andrographolide among others), and (iv) pain/cold relief (e.g., sustained-release formulations containing Naproxen Sodium and Pseudoephedrine Hydrochloride). In digestive and supportive care, the company provides treatments and compounds such as Omeprazole and other ingredients/formulations noted in its product lineup. The firm also mentions related health products such as sanitizers and protective masks, reflecting broader participation in healthcare-adjacent consumer items.
Commercially, CPHI distributes its products through third-party distributors and augments coverage via its own sales offices and a direct sales team. The description indicates the company maintains a network of 16 sales offices and employs roughly 1,000 sales professionals, supporting penetration into hospitals and retail channels across mainland China. This channel strategy is typical for specialty/generic manufacturers where hospital formularies and regional distributor relationships can materially affect sales momentum.
On operations and cost structure, manufacturing pharmaceuticals generally involves a multi-step BOM (bill of materials) including active pharmaceutical ingredients (APIs) and excipients, formulation work, packaging materials, quality control/assurance, and compliance documentation. While specific BOM details are not provided, CPHI’s span of injectables and oral dosage forms implies diversified procurement and manufacturing complexity (e.g., sterility/bioburden controls for injectables; stability and dose uniformity controls for solids/liquids).
Financially, the provided snapshot reflects negative profitability metrics on a trailing twelve-month basis (e.g., negative margins and cash-flow-related ratios in the dataset). Such performance patterns often occur in developing or reconfiguring manufacturing footprints, during demand fluctuations, pricing pressure in generics, or periods of elevated costs (including SG&A and compliance-related expenses). For investors, the key items to monitor would typically include gross margin stability, working-capital efficiency (receivables, inventory, and payables), R&D intensity (the dataset shows R&D-to-revenue), and cash generation.
In terms of key people and governance, the company identifies Zhilin Li as Chairman, President, and Chief Executive Officer. The company’s historical roots trace to the establishment of Helpson Medical & Biotechnology Co. in 1993 in Haikou, Hainan (a milestone often cited in describing the company’s origins). Overall, CPHI’s stated aim is to integrate drug development, manufacturing, and marketing to serve multiple disease areas, while scaling distribution reach across China.
